Is NGSX.OB a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

150 people get NGSX.OB articles and Market Currents by email alert.

Get email alerts on NGSX.OB »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

NeurogesX: Positive Momentum
Zacks Investment Research • Wed, Jun 10, 2009
NeurogesX: Qutenza Nearing Approval, Looks Promising
Zacks Investment Research • Mon, May 11, 2009
NeurogesX Awaiting Dual Regulatory Decisions
Mike Havrilla • Sun, May 10, 2009
NeurogesX Fundamentals Improve
Zacks Investment Research • Tue, Mar 24, 2009
Now's The Time To Hop Aboard NeurogesX
Brett Scott • Wed, Sep 5, 2007
Three Reasons to Be Optimstic on NeurogesX
Brett Scott • Thu, Aug 16, 2007
Neurogesx: A Speculative Biotech Investment
Brett Scott • Tue, Jul 24, 2007
Broken IPO NeurogesX Names BioMarin Pharma CEO as New Chairman
Richard Shonfeld • Wed, May 30, 2007

To learn more about Seeking Alpha Pro, click here.

3 Best Biotech Stocks For This Week (Part V)
Jorge Aura • Mon, Oct 8, 2012 • 2 Comments
Transcept: The Intermezzo Launch Is Underway
Smith On Stocks • Tue, Apr 24, 2012 • 2 Comments
Noteworthy Institutional 5% Ownership Filings This Week In Healthcare And Tech
GuruFundPicks • Thu, Mar 15, 2012
Aria And Talon: Is An Advisory Panel Meeting A Profitable Trading Catalyst?
BinaryLeverage • Sun, Mar 4, 2012 • 11 Comments
12 Healthcare Companies Expecting Major February Catalysts
Spencer Knight • Wed, Feb 1, 2012 • 8 Comments
FDA Pending Catalysts For 5 Biotechs
Todd Johnson • Wed, Jan 25, 2012 • 20 Comments
9 Biotech Companies With FDA Approval Decision Dates In Q1 2012
David Zanoni • Mon, Dec 12, 2011 • 3 Comments
3 Biotech Buys Based on Thursday's Losers
GuruFundPicks • Fri, Sep 30, 2011 • 2 Comments
What Happens After Intermezzo's Likely FDA Approval
Smith On Stocks • Mon, Jul 11, 2011 • 5 Comments
Accipiter Capital's Most Favorite Stock Picks
Insider Monkey • Sun, Jun 5, 2011 • 7 Comments
22 Companies With Market Cap Over $50 Million and 100%-Plus Sales Growth Forecast for 2011-12
Rash Menaria • Mon, Feb 28, 2011 • 8 Comments
U.S. Pharma: Latest Analyst Actions
Alacra Pulse Check Blog • Sun, Dec 5, 2010 • 4 Comments
Biotech CROs Take Center Stage in Recent Deals
The Burrill Report • Sun, May 2, 2010 • 1 Comment
Volume Talks Wednesday: A Bullish Biotech Breakout Option Play
Option Maestro • Thu, Mar 25, 2010
NeurogesX: Next Stop, U.S. Market
EP Vantage • Thu, Nov 19, 2009 • 1 Comment
BioMed News Bytes: GeoVax, Cerus, Discovery Labs, NeurogesX
Mike Havrilla • Wed, Nov 18, 2009
FDA Calendar Extreme Trades: 85 Single Digit Stocks
Mike Havrilla • Wed, Oct 14, 2009 • 4 Comments
The Top 25
Bespoke Investment Group • Thu, Oct 1, 2009 • 1 Comment
FDA Calendar Updates: NeurogesX, Thoratec
Mike Havrilla • Thu, Aug 6, 2009
FDA Calendar Updates: Celgene, NeurogesX, Rigel
Mike Havrilla • Fri, Jul 24, 2009

NeurogesX's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Mon, Aug 6, 2012
NeurogesX Inc. Q1 2010 Earnings Call Transcript
Tue, May 11, 2010
NeurogesX Inc. Q4 2007 Earnings Call Transcript
Wed, Mar 26, 2008

NeurogesX Reports Third Quarter 2012 Results

GlobeNewswire (Nov 14, 2012)
NeurogesX to Present at Rodman & Renshaw 14th Annual Healthcare Conference

GlobeNewswire (Sep 5, 2012)
NeurogesX' NGX-1998 Well-Tolerated Treatment Demonstrated Clear Dose-Response in Patients

GlobeNewswire (Aug 30, 2012)
NeurogesX to Present at Wedbush PacGrow 2012 Life Sciences Management Access Conference

GlobeNewswire (Aug 9, 2012)
NeurogesX Provides Regulatory Update for NGX-1998 Clinical Program

GlobeNewswire (Aug 7, 2012)
NeurogesX Reports Second Quarter 2012 Results

GlobeNewswire (Aug 3, 2012)
NeurogesX Receives Additional Notice of Allowance Covering NGX-1998 in U.S.

GlobeNewswire (Aug 2, 2012)
NeurogesX to Hold Conference Call to Discuss Second Quarter 2012 Results

GlobeNewswire (Jul 27, 2012)
NeurogesX Partner Astellas Enrolls First Patient in EU Clinical Trial for QUTENZA(R) (8% capsaicin patch)

GlobeNewswire (Jul 24, 2012)
NeurogesX NGX-1998 Phase 2 Study Data to be Presented at World Congress on Pain

GlobeNewswire (Jul 16, 2012)
Trading in NeurogesX Common Stock to Move From NASDAQ to OTCBB

GlobeNewswire (Jun 29, 2012)
NeurogesX Receives Notice of Two U.S. Patent Allowances Covering NGX-1998

GlobeNewswire (Jun 19, 2012)
NeurogesX Issued Japanese Patent for NGX-1998

GlobeNewswire (Jun 18, 2012)
NeurogesX Reports First Quarter 2012 Results

GlobeNewswire (May 3, 2012)
NeurogesX to Hold Conference Call to Discuss First Quarter 2012 Results

GlobeNewswire (Apr 27, 2012)
NeurogesX Receives Determination Letter From NASDAQ

GlobeNewswire (Apr 20, 2012)
NeurogesX Engages JSB-Partners to Execute Business Development Strategy

GlobeNewswire (Apr 17, 2012)
NeurogesX Provides Update on NGX-1998 Clinical Program

GlobeNewswire (Apr 11, 2012)
NeurogesX Appoints Ronald Martell President and Chief Executive Officer

GlobeNewswire (Jan 3, 2012)
NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)

GlobeNewswire (Dec 15, 2011)

NGSX.OB vs. ETF Alternatives

Company Description

We are a biopharmaceutical company focused on developing and commercializing novel pain management therapies. We are assembling a portfolio of pain management product candidates based on known chemical entities to develop innovative new therapies which we believe may offer substantial advantages... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, April 11, 2012, 11:04 AM Shares of microcap drug developer NeurogesX (NGSX +30%) soar after saying the FDA has accepted its request for a meeting to discuss ongoing clinical studies of NGX-1998, its product candidate for neuropathic pain. Phase 2 studies were completed at the end of 2011. Comment! [Healthcare, On the Move]
Friday, February 10, 2012, 10:20 AM NeurogesX (NGSX) -20.6% after yesterday's news that an FDA advisory committee did not recommend approval for its Qutenza patch as a treatment for nerve pain related to HIV-associated peripheral neuropathy. Comment! [Healthcare, On the Move]
Thursday, February 9, 2012, 2:36 PM A FDA panel votes 12 to 0 that the Qutenza patch offered by NeurogesX (NGSX) doesn't treat pain in patients afflicted with HIV. Shares are still under a trading halt. Comment! [Healthcare]
Thursday, February 9, 2012, 8:35 AM Trading in both Astex Pharmaceuticals (ASTX) and NeurogesX (NGSX) is halted ahead of a FDA panel meeting on separate drugs for the firms. (FDA agenda: ASTX, NGSX) Comment! [Healthcare]
Tuesday, February 7, 2012, 8:58 AM NeurogesX (NGSX) -21.9% premarket following cautious reports related to FDA approval of its patch for HIV pain. The prescription-strength capsaicin patch didn’t meet its goals in studies for reducing pain caused by neuropathy linked to the virus, an FDA report says. Comment! [Healthcare, On the Move]
Tuesday, November 17, 2009, 9:00 AM Premarket gainers: SMTL +30%. AGO +12%. HLCS +12%. CSE +11%. APWR +11%. DDS +10%. NGSX +9%. SINA +7%. SKS +6%. EJ +6%. CTIC +6%. DPTR +5%. MPEL +4%.
Losers: PSUN -22%. SPWRA -16%. JEC -10%. AOB -9%. BCRX -9%. IRE -9%. CPSL -8%. SII -7%. AIB -7%. NLST -6%. TGP -6%. HOLX -5%. THOR -4%. 1 Comment

NGSX.OB NeurogesX, Inc.

NGSX.OB

NeurogesX, Inc.